Current stock page

Stock Analysis

Stoke Therapeutics, Inc. (STOK) Stock Analysis

Stoke Therapeutics, Inc. (STOK) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

STOK Stock Analysis Summary

Stoke Therapeutics, Inc. (STOK) currently has an AIQ Score of 42/100, indicating a bearish setup. Risk is the strongest factor at 59/100. Value is the weakest current factor at 22/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

STOK at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$26.68
AIQ Score42/100
Overall ViewBearish
Technical Analysis ConsensusBuy
Market Cap$1.82B
P/E Ratio (TTM)-7.04
Forward P/E—
EPS (Q3 FY2026)-$1.08
Revenue (Q3 FY2026)$11.26M
Dividend Yield (TTM)0.00%
Beta0.96
Volume420.23K
52-week range$22.05-$40.22
RSI 1451.32
50-Day SMA$26.45
200-Day SMA$30.79
Analyst Price Target$43.00
Next EarningsMar 15, 2027
As of Nov 13, 2026 · Market close

STOKStoke Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 2/10
$26.68+$0.48 (+1.83%)

Latest quote

  • Momentum
    47
  • Value
    22
  • Quality
    42
  • Risk resilience
    59
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

STOK Stock Analysis Summary

Stoke Therapeutics, Inc. (STOK) currently has an AIQ Score of 42/100, indicating a bearish setup. Risk resilience is the strongest factor at 59/100. Value is the weakest current factor at 22/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, STOK has AIQ Score of 42/100 with Risk resilience base of 59/100 and fading Value at 22/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Risk resilience (59/100) leads while Value (22/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 1.83% stock move · STOK classified in Biotechnology.

Current Evidence

BearishSTOK is in a bearish AIQ regime; Risk resilience is the strongest visible factor at 59/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is STOK Bullish or Bearish Right Now?

STOK currently has a bearish overall setup. Risk Resilience is the strongest factor at 59/100, while Value is weakest at 22/100. The current evidence suggests a bearish setup.

Bull Case
  • - Price is +0.86% above its 50-day SMA.
  • - Analyst target implies +61.17% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (25 vs 11).
Bear Case
  • - Value is the current constraint at 22/100.
  • - Momentum is weak at 47/100.
  • - Price is -13.34% below its 200-day SMA.

Current Consensus

STOK's Technical Analysis Consensus is currently Buy, with 25 buy, 10 neutral, and 11 sell votes. STOK's 14-day RSI is 51.32, which places the stock in a neutral momentum range. STOK's beta is 0.96, indicating market sensitivity broadly in line with the market.

Signal Confidence
Moderate agreement

What Changed in STOK?

The largest recent change in STOK is Momentum moving up by 6.0 points over the available 7-day comparison window. Risk Resilience remains the strongest visible factor.

AIQ Score
+2.0
Momentum
+6.0
Quality
+1.0
Risk
-1.0

What Would Change the STOK Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

STOK Decision Framework

Public evidence layers, setup checks, and risk context for Stoke Therapeutics, Inc..

Stoke Therapeutics, Inc. (STOK) Stock Analysis

Stoke Therapeutics, Inc. has an AIQ Score of 42/100 in a Bearish regime. Risk is strongest at 59/100. Beta is 0.96, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextSTOK is in a Bearish AIQ regime with score 42/100.
Signal ConflictThe primary conflict is that risk leads at 59/100 while value lags at 22/100.
Factor EvidenceMomentum 47/100 · Value 22/100 · Quality 42/100 · Risk 59/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthWait

Risk is the strongest factor at 59/100.

TimingFail

Momentum is 47/100 and RSI (14) is 51.3.

Regime fitFail

STOK is in a Bearish regime at 42/100.

Risk controlWait

Risk factor is 59/100 with beta 0.96 and annual volatility 53.19%.

ConflictWait

Current conflict: risk leads at 59/100 while value lags at 22/100.

AIQ Score
42/100
Price
$26.68
Beta
0.96
RSI (14)
51.3

STOK Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

STOK Fundamentals

STOK valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$11.26M
Net income
-$73.64M
Free cash flow
-$65.54M
View full STOK fundamental analysis

STOK Technical Analysis

STOK technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Buy
RSI 14
51.32
Price vs SMA-50
+0.86%
View full STOK technical analysis

STOK Stock Catalysts

Track STOK earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 15, 2027
Analyst target
$43.00
News items
4
View STOK earnings and stock catalysts

STOK Dividend Analysis

STOK dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View STOK dividend history and analysis

STOK Financial Data

STOK revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$11.26M
EPS
-$1.08
Periods
8
View STOK financials

STOK Risk Analysis

STOK volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.96
Risk score
59/100
1Y volatility
53.19%
View STOK risk analysis

STOK Stock News

STOK stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 15, 2026
Sentiment
—
Read STOK stock news

STOK vs Biotechnology Peers

Current peer cohort: STOK · SYRE · TARS · TGTX · TNGX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
STOK
Current stock
42/10022/10047/10059/1000.2353.19%Current
SYRE
Spyre Therapeutics, Inc.
64/10044/10081/10053/1002.5766.66%STOK vs SYRE
TARS
Tarsus Pharmaceuticals, Inc.
65/10075/10076/10059/1000.3645.02%STOK vs TARS
TGTX
TG Therapeutics, Inc.
76/10065/10093/10063/1001.7446.06%STOK vs TGTX
TNGX
Tango Therapeutics, Inc.
61/100—60/10038/1001.61101.07%STOK vs TNGX
Pairwise Compare links: SYRE · TARS · TGTX · TNGXSTOK vs SYRESTOK vs TARSSTOK vs TGTXSTOK vs TNGXCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a STOK stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for STOK: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-7.04
As of Nov 13, 2026
Revenue growth
5.86%
Gross margin
88.52%
Current debt / equity
0
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$11.26M
Quarter net income
-$73.64M
Quarter free cash flow
-$65.54M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Mixed
RSI 14
51.32
MACD
0.24

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
59/100
Beta
0.96
Annual volatility
53.19%
Max drawdown
-41.33%

STOK Stock FAQ

What is STOK stock price today?

Stoke Therapeutics, Inc.'s current stock price is $26.68. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is STOK bullish or bearish right now?

STOK's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is STOK's market cap?

STOK's market cap is $1.82B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is STOK's current P/E ratio?

STOK's current P/E ratio is -7.04 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is STOK's RSI?

STOK's 14-day RSI is 51.32 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is STOK above its 50-day and 200-day moving averages?

STOK is 0.86% from its 50-day SMA and -13.34% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is STOK's next earnings date?

STOK's next earnings date is currently listed as Mar 15, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does STOK pay a dividend?

STOK's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.